Stocktoria
GENELUX Corp GNLX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-01-26
GENELUX Corp financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $8,000 | $8,000 | $170,000 | $11.1M |
| R&D expense | $19.9M | $19.0M | $12.8M | $9.1M |
| Operating income | -$33.2M | -$31.7M | -$24.2M | -$3.0M |
| Income tax | — | — | — | $1.1M |
| Net income | -$32.1M | -$29.9M | -$28.3M | -$5.2M |
| EPS (diluted) | $-0.86 | $-0.95 | $-1.16 | $-0.57 |
| Operating cash flow | -$25.3M | -$21.2M | -$20.3M | -$3.6M |
| Free cash flow | -$26.4M | -$21.6M | -$21.3M | -$3.6M |
| Cash & equivalents | $5.3M | $8.6M | $9.4M | $397,000 |
| Total assets | $19.0M | $34.7M | $27.9M | $5.5M |
| Total liabilities | $7.5M | $8.4M | $8.4M | $41.3M |
| Shareholders' equity | $11.5M | $26.3M | $19.5M | -$35.8M |
Growth · year-over-year · Revenue CAGR -91%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +0.0% | -95.3% | -98.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.